Abstracts tagged "autoimmune diseases"

Abstract Number: 0016 • ACR Convergence 2023
Role of TP53 in Inflammatory Reprogramming of Rheumatoid Arthritis Synovial Fibroblasts
Anil Singh and Salahuddin Ahmed, Washington State university, Spokane, WA
Background/Purpose: TP53, a tumor-suppressor protein known as the guardian of the genome, plays a critical role in regulating genomic stability and cellular function. When TP53…
Abstract Number: 0086 • ACR Convergence 2023
Optimizing PD-1 Agonist Signaling with Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody
Stephen Parmley, Benjamin Szylyk, Richard Frank, Matthew Hsu, Polina Brodsky, Cailin Sibley, Paul Lizzul and Martin Dahl, AnaptysBio, San Diego, CA
Background/Purpose: Checkpoint antagonist therapeutics have transformed the field of oncology while advancing the understanding of adequate checkpoint activity in preventing autoimmunity. Checkpoint agonism represents a…
Abstract Number: 0218 • ACR Convergence 2023
Incidence and Risk Factors for Breakthrough COVID-19 After Tixagevimab/Cilgavimab Among Patients with Systemic Autoimmune Rheumatic Diseases
Yumeko Kawano¹, Xiaosong Wang¹, Naomi Patel², Grace Qian¹, Emily Kowalski¹, Katarina Bade³, Kathleen Vanni¹, Accelerating Medicines Partnership (AMP): RA/SLE¹, Zachary Williams², Claire Cook², Shruthi Srivatsan², Zachary Wallace⁴ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Massachusetts General Hospital, Newton, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: During the height of the COVID-19 pandemic in the United States, tixagevimab/cilgavimab (Evusheld), a combination of monoclonal antibodies directed against the SARS-CoV2 spike protein,…
Abstract Number: 0336 • ACR Convergence 2023
Core Signs Associated with the Subtypes of Cutaneous Lupus Erythematosus: Concept Elicitation Interviews with Dermatologists and Rheumatologists
victoria werth¹, Annegret Kuhn², Joseph F. Merola³, Joerg Wenzel⁴, Cristina Vazquez-Mateo⁵, Sanjeev Roy⁶, Erik Thomas⁵, Oliver Guenther⁷, Ying Sun⁷, Alexandra Lauer⁷, Almary Guerra Rodriguez⁸, Patricia Koochaki⁹ and Paul Kamudoni⁷, ¹University of Pennsylvania, Wynnewood, PA, ²Amsterdam University Medical Center, Amsterdam, Netherlands, and University of Münster, Münster, Germany, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴University Hospital of Bonn, Bonn, Germany, ⁵EMD Serono, Billerica, MA, ⁶Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany, ⁷the healthcare business of Merck KGaA, Darmstadt, Germany, ⁸Laife Reply GmbH, Frankfurt am Main, Germany, ⁹ICON Clinical Research LLC, Raleigh, NC
Background/Purpose: Greater understanding of cutaneous signs and symptoms is needed to comprehensively define and measure cutaneous disease activity in lupus erythematosus. Herein, we interviewed dermatologic…
Abstract Number: 0581 • ACR Convergence 2023
Performance Characteristics of a Novel, Fully Automated Multiplexed Immunoassay Microarray Prototype for the Serological Detection of Eleven IgG Autoantibodies Commonly Found in Connective Tissue Diseases
Daphne Bijlsma, Ewa Lukasik, Michael Hausmann, Gerber Gomez, Christine Ginocchio and Emmanuel Moreau, Quotient Suisse SA, Eysins, Switzerland
Background/Purpose: Detection of autoantibodies is key for the identification and prognosis of patients with connective tissue diseases (CTD); however, some current testing methods are manual,…
Abstract Number: 0800 • ACR Convergence 2023
CD4+ CD96+ T Cells Are Pathogenic Effector Cells in Giant Cell Arteritis
Shozo Ohtsuki¹, Jose Morales², Yuki Sato², Chenyao Wang², Matthew Koster³, Kenneth Warrington³, Gerald J. Berry⁴, Jorg Goronzy³ and Cornelia M. Weyand⁵, ¹Mayo Clinic College of Medicine and Science, Stanford University School of Medicine, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, ³Mayo Clinic, Rochester, MN, ⁴Stanford University School of Medicine, Stanford, CA, ⁵Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: In Giant Cell Arteritis (GCA), granulomatous infiltrates occupy the vessel wall and elicit maladaptive vascular remodeling with intimal hyperplasia. The major cell types of…
Abstract Number: 1003 • ACR Convergence 2023
A Multidisciplinary Obstetric-Medicine/Rheumatology Specialty Clinic in the United States: A Five Year Analysis
Griffin Reed¹, Joyce Mathew¹, Kelsey Rigby², Mery Deeb³, Elena Cravens¹, Anthony Reginato⁴, Gofran Tarabulsi⁵ and Joanne Cunha⁶, ¹Brown University, Providence, RI, ²Dartmouth Hitchcock Medical Center, Falmouth, MA, ³Brown University, Warwick, RI, ⁴The Warren Alpert Medical School of Brown University, Providence, RI, ⁵Women and Infants Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, ⁶The Warren Alpert Medical School of Brown University, Riverside, RI
Background/Purpose: Rheumatic disorders frequently affect women of childbearing age. These diseases and medications used to treat them can have adverse effects on fertility and fetuses.…
Abstract Number: 1141 • ACR Convergence 2023
COVID-19 Vaccination Status and Adverse Events Following SARS-CoV-2 Vaccine in Autoimmune Inflammatory Rheumatic Disease (AIRD) Patients: A Single Center Experience
Vincent Luceño¹, Peter Paolo Daleon¹ and Sandra Navarra², ¹University of Santo Tomas Hospital, City of Manila, Philippines, ²University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines
Background/Purpose: Autoimmune inflammatory rheumatic diseases (AIRD) were associated with an increased risk for COVID-19 infection, worse clinical outcomes, and COVID-19- related deaths. Vaccines carry the…
Abstract Number: 1380 • ACR Convergence 2023
Synergistic Dose Effects of Extra X Chromosome in Development of Sjogren’s Syndrome in Klinefelter and Triple X Syndromes
Anna-Kay Palmer¹ and Irene Tan², ¹Albert Einstein Medical Center, Philadelphia, PA, ²Einstein Medical Center Philadelphia, Bala Cynwyd, PA
Background/Purpose: Immune-related genes located on the X chromosome are known to be important in the regulation of sex hormones and immune tolerance. It has been…
Abstract Number: 1607 • ACR Convergence 2023
Autoantibodies to Transcription Factor a Mitochondria Link Mitochondrial Damage and Thrombosis in Systemic Lupus Erythematosus
Eduardo Gomez-Banuelos¹, Alessandra Ida Celia², Maria Isabel Trejo Zambrano³, Merlin Paz³, Erika Darrah³, Daniel Goldman⁴, Michelle Petri⁴ and Felipe Andrade³, ¹The Johns Hopkins University, Baltimore, MD, ²John Hopkins University of Medicine, Rome, Italy, ³Johns Hopkins University, Baltimore, MD, ⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Upon activation with interferon (IFN) and RNP-immune complexes, defective mitophagy in neutrophils results in the release of mtDNA in complex with transcription factor A…
Abstract Number: 1800 • ACR Convergence 2023
Factors Associated with an Electronic Health Record-Based Definition of Post-Acute Sequelae of COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases
Naomi Patel¹, Xiaosong Wang², Yumeko Kawano², Abigail Schiff², Rathnam Venkat², Claire Cook¹, Kathleen Vanni², Grace Qian², Katarina Bade², Shruthi Srivatsan¹, Krishan Guzzo¹, Zachary Williams¹, Emily Kowalski², Alene Saavedra², Jeffrey Sparks³ and Zachary Wallace⁴, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Newton, MA
Background/Purpose: Immunosuppression for treatment of systemic autoimmune rheumatic diseases (SARDs) is associated with increased risk of severe acute COVID-19 due to blunted vaccine responses and…
Abstract Number: 1931 • ACR Convergence 2023
Anti-Ku Antibodies: A Case Series
Raquel Ugena García¹, Cristina Calomarde Gomez¹, Joan Climent² and Lourdes Mateo Soria², ¹Rheumatology department. Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Anti-Ku antibodies (Abs) were initially described in patients with polymyositis and scleroderma. Subsequently, an association has been demonstrated with other systemic autoimmune diseases (SADs),…
Abstract Number: 2147 • ACR Convergence 2023
Safety and Effectiveness in Cycling Between Non-Selective and Selective JAKi in a Multi-Center Registry of Rheumatoid Arthritis in the Middle East
Rajaie Namas¹, Jawahir Alameri², Sarah Al Qassimi², Ha-Neul Yu³, Mohamed Elarabi², Hani Shatnawi⁴, Lara Memisoglu², Ahlam Al Marzooqi⁵, Asia Mubashir² and Eduardo Mysler⁶, ¹Medical Subspecialties Institute, Division of Rheumatology, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, ²Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, ³New York University Abu Dhabi, Abu Dhabi, United Arab Emirates, ⁴Princess Basma Teaching Hospital, Amman, Jordan, ⁵Al Qassimi Hospital, Sharjah, United Arab Emirates, ⁶Organización Medica de Investigación, Buenos Aires, Argentina
Background/Purpose: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease. Strategies for addressing treatment failure with TNF inhibitors according to the recent EULAR recommendations include…
Abstract Number: 2442 • ACR Convergence 2023
Neutrophils Induce Contact-Dependent Expansion of Arthritogenic Th17 Cells and Are Necessary for Disease in Experimental Ankylosing Spondylitis
Hillary Struthers¹, Emily Vance¹, Kofi Asare-Konadu¹, Holly Rosenzweig² and Ruth Napier¹, ¹Oregon Health & Science University, Portland, OR, ²VA Portland Healthcare System, Portland, OR
Background/Purpose: Ankylosing spondylitis (AS) patients have irregular neutrophil responses, as indicated clinically by neutrophilia and increased neutrophil to lymphocyte ratios that positively associate with disease…
Abstract Number: 2574 • ACR Convergence 2023
Are Patients Classified as IPAF More Likely to Also Meet SLE Criteria by 2019 EULAR/ACR Than by SLICC?: An Abstract
Gabriela Martinez Zayas¹, David Karp¹ and Elena Joerns², ¹UT Southwestern Medical Center, Dallas, TX, ²University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) is a research classification proposed by the European Respiratory Society and American Thoracic Society Task Force for those…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].